YONKERS, N.Y., Dec. 11 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corporation (OTC Bulletin Board: ADVR) announced today that Elma S. Hawkins,
Ph.D., MBA has been appointed to the Company's Board of Directors and named a
Member of the Executive Management Committee, effective immediately.
Dr. Hawkins has more than 20 years of business, management, regulatory and
scientific experience in the pharmaceutical and biotechnology industries. She
played a pivotal role in bringing a number of drugs to the market in the
United States and Europe.
"I am delighted to welcome Dr. Hawkins to the Board. With over two
decades of strong drug development and management experience, I am confident
that Dr. Hawkins' expertise will strengthen Advanced Viral Research's ability
to move its lead product, AVR118, through clinical trials towards
commercialization", said Eli Wilner, Chairman of Advanced Viral Research
Corporation.
Dr. Hawkins will remain Vice Chairman of Antigenics (Nasdaq: AGEN), a
biotechnology company that is working to develop personalized
immunotherapeutics and revolutionary treatments for cancers, infectious
diseases and autoimmune disorders. Prior to her position at Antigenics, Dr.
Hawkins served in a number of senior positions in corporate development,
strategic planning, and regulatory and clinical affairs at Genzyme Corporation
and Genzyme Tissue Repair. In addition, Dr. Hawkins held preclinical, clinical
and regulatory positions at Warner-Lambert/Parke-Davis Pharmaceuticals and at
the Center for the Study of Drug Development at Tufts Medical School.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm dedicated to improving patients' lives by researching,
developing and bringing to market new and effective therapies for viral and
other diseases. ADVR's AVR118 (formerly known as Product R) represents a
biopolymer chemistry that possesses novel immunomodulator activity. This
peptide-nucleic acid, which to date has shown no indication of human toxicity,
appears to stimulate the proinflammatory responses required to combat viral
infections such as AIDS and human papilloma virus and to dampen aberrant
autoimmune-type inflammatory responses, such as occur in patients with
rheumatoid arthritis. AVR118 is in clinical trials in Israel for the
treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company. The Company undertakes no obligation to update or revise the
information contained in this announcement whether as a result of new
information, future events or circumstances or otherwise.
Contact: Ronnie Welch or Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch or Kelly Cinelli of CWR &
Partners, +1-508-222-4802, for Advanced Viral Research Corp.
|
